Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

• DOI: 10.1158/2326-6066.cir-22-0910
• Publication Date: 2023-05-31T20:38:10Z
• Authors: Beatriz Aranda-Or...; Isabelle Chion-So...; Jordan Skinner; Steven Grudman; Ben Mumford; Chantel Dixon; Jorge Postigo Fer...; Piril Erler; Phillipe Duchateau; Agnes Gouble; Roman Galetto; Laurent Poirot
• Keywords: B-Lymphocytes; Lymphoma, B-Cell; T-Lymphocytes; Antigens, CD19; Receptors, Antigen, T-Cell; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Immunotherapy, Adoptive; Research Articles; 3. Good health

Abstract Despite the remarkable success of autologous chimeric antigen receptor (CAR) T cells, some patients relapse due to tumor escape and low or uneven expression, among other mechanisms. Therapeutic options after are limited, emphasizing need optimize current approaches. In addition, there is a develop allogeneic “off-the-shelf” therapies from healthy donors that readily available at time treatment decision can overcome limitations To address both challenges simultaneously, we generated CD20xCD22 dual CAR cell. Herein, demonstrate CD20x22 cells display robust, sustained dose-dependent activity in vitro vivo, while efficiently targeting primary B-cell non–Hodgkin lymphoma (B-NHL) samples with heterogeneous levels CD22 CD20. Altogether, provide preclinical proof-of-concept data for an cell mechanisms resistance T-cell B-NHL, providing potential alternative CD19 targeting.